var data={"title":"Betamethasone (topical): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Betamethasone (topical): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/718350?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=betamethasone-topical-patient-drug-information\" class=\"drug drug_patient\">see &quot;Betamethasone (topical): Patient drug information&quot;</a> and <a href=\"topic.htm?path=betamethasone-topical-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Betamethasone (topical): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780933\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>AlphaTrex [DSC];</li>\n      <li>Diprolene;</li>\n      <li>Diprolene AF;</li>\n      <li>Luxiq;</li>\n      <li>Sernivo</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780934\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Betaderm;</li>\n      <li>Beteflam;</li>\n      <li>Betnesol;</li>\n      <li>Celestoderm V;</li>\n      <li>Celestoderm V/2;</li>\n      <li>Diprolene;</li>\n      <li>Diprosone;</li>\n      <li>Luxiq;</li>\n      <li>Prevex B;</li>\n      <li>Rivasone;</li>\n      <li>Rolene;</li>\n      <li>Rosone;</li>\n      <li>Valisone Scalp Lotion</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780937\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Corticosteroid, Topical</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780969\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Base  dosage on severity of disease and patient response. Use lowest dose possible for shortest period of time to avoid HPA axis suppression. Therapy should be discontinued when control is achieved.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Corticosteroid-responsive dermatoses:</b>  Topical:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cream, augmented formulation: Betamethasone dipropionate 0.05%: Apply once or twice daily (maximum: 50 g weekly).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cream, unaugmented formulation:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Betamethasone dipropionate 0.05%: Apply once daily; may increase to twice daily if needed</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Betamethasone valerate 0.1%: Apply 1 to 3 times daily. <b>Note: </b> Once- or twice-daily applications are usually effective.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Foam: Apply to the scalp twice daily, once in the morning and once at night. <b>Note:</b> Reassess if no improvement after 2 weeks of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gel, augmented formulation: Apply once or twice daily; rub in gently (maximum: 50 g weekly). <b>Note:</b> Reassess if no improvement after 2 weeks of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lotion, augmented formulation: Betamethasone dipropionate 0.05%: Apply a few drops once or twice daily (maximum: 50 mL weekly). <b>Note:</b> Reassess if no improvement after 2 weeks of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lotion, unaugmented formulation:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Betamethasone dipropionate 0.05%: Apply a few drops twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Betamethasone valerate 0.1%: Apply a few drops twice daily; may consider increasing dose for resistant cases. Following improvement, may apply once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ointment, augmented formulation: Betamethasone dipropionate 0.05%: Apply once or twice daily (maximum: 50 g weekly). <b>Note:</b> Reassess if no improvement after 2 weeks of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ointment, unaugmented formulation: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Betamethasone dipropionate 0.05%: Apply once daily; may increase to twice daily if needed</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Betamethasone valerate 0.1%: Apply 1 to 3 times daily. <b>Note:</b> Once- or twice-daily applications are usually effective.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Plaque psoriasis:</b> Topical: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Patch [Canadian product]: Betamethasone valerate: Apply 1 patch (2.25 mg) to each affected area once daily [up to 5 patches (11.25 mg) may be applied daily]; maximum duration of therapy: 30 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Spray, unaugmented formulation: Betamethasone dipropionate 0.05%: Apply twice daily for up to 4 weeks</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780968\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=betamethasone-topical-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Betamethasone (topical): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Base dosage on severity of disease and patient response. Use lowest dose possible for shortest period of time to avoid HPA axis suppression. Therapy should be discontinued when control is achieved.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Corticosteroid-responsive dermatoses:</b> Topical:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: Cream, lotion or ointment: Unaugmented formulation: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents: Cream, gel, lotion, or ointment: Augmented formulation: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780970\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Use the lowest effective dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24173866\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780971\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780990\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, External, as dipropionate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.05% (15 g, 45 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, External, as dipropionate augmented [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diprolene AF: 0.05% (15 g, 50 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.05% (15 g, 50 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, External, as valerate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.1% (15 g, 45 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Emulsion, External, as dipropionate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sernivo: 0.05% (120 mL) [contains cetostearyl alcohol, methylparaben, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Foam, External, as valerate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Luxiq: 0.12% (50 g, 100 g) [contains alcohol, usp, cetyl alcohol, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.12% (50 g, 100 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel, External, as dipropionate augmented [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AlphaTrex: 0.05% (15 g [DSC], 50 g [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.05% (15 g, 50 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Lotion, External, as dipropionate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.05% (60 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Lotion, External, as dipropionate augmented [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diprolene: 0.05% (30 mL, 60 mL) [contains isopropyl alcohol, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.05% (30 mL, 60 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Lotion, External, as valerate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.1% (60 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ointment, External, as dipropionate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.05% (15 g, 45 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ointment, External, as dipropionate augmented [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diprolene: 0.05% (15 g, 50 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.05% (15 g, 45 g, 50 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ointment, External, as valerate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.1% (15 g, 45 g)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780936\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46816957\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Patch, Transdermal, as valerate:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Beteflam: 2.25 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780975\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Topical: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cream, ointment: Apply topical sparingly to affected areas. Not for use on broken skin or in areas of infection. Do not apply to wet skin unless directed; do not cover with occlusive dressing. Do not apply very high potency agents to face, groin, axillae, or diaper area. Not for oral, ophthalmic, or intravaginal use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lotion: Apply topical sparingly to affected areas. Massage in gently until lotion disappears. Not for use on broken skin or in areas of infection. Do not apply to wet skin unless directed; do not cover with occlusive dressing. Do not apply very high potency agents to face, groin, axillae, or diaper area. Not for oral, ophthalmic, or intravaginal use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foam: Invert can and dispense a small amount onto a saucer or other cool surface. Do not dispense directly into hands. Pick up small amounts of foam and gently massage into affected areas until foam disappears. Repeat until entire affected scalp area is treated. Do not cover with occlusive dressing unless directed otherwise by health care provider. Not for ophthalmic use. Avoid getting into eyes. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Patch [Canadian product]: Clean and dry area to be treated prior to each application. May cut patch to size to cover lesion. Peel off protective film and apply adhesive medicated side to affected area; patch should be worn for 20 to 24 hours. After removing patch wait at least 30 minutes before applying a new one. Keep dry; if patch becomes wet, remove and wait until next scheduled dose before applying a new one. Do not cover with occlusive dressing. Patch should not be reused if it comes off; if edges of patch start to lift, apply medical adhesive tape to detached part only. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Spray: Spray directly onto affected areas (spray only enough to sufficiently cover the area); rub in gently and wash hands after applying. Shake well before use. Do not use if atrophy is present at the treatment site. Do not cover with occlusive dressing unless directed otherwise by health care provider. For topical use only; not for oral, ophthalmic or vaginal use; avoid use on the face, scalp, axilla, groin, or other intertriginous areas.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780941\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dermatoses:</b> Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Dermatoses of the scalp (foam):</b> Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Plaque psoriasis (spray; patch [Canadian product]):</b> Treatment of mild to moderate plaque psoriasis in patients 18 years and older.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780928\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Luxiq may be confused with Lasix</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780952\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Local: Application site reactions (2% to 44%; includes burning, stinging, and itching; most reactions were mild)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Tingling (2%; paresthesia at application site)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin atrophy (children: 10%), acneiform eruption (2%), alopecia (2%), pruritus (&le;2%), dermatitis (&lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Conjunctivitis (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined: Endocrine &amp; metabolic: HPA axis suppression</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Atrophic striae, bullous dermatitis, capillary fragility, contact dermatitis, dermal ulcer (of psoriatic lesions), dysgeusia, dyshidrotic eczema, eczema, edema, epidermolysis, erythema, exacerbation of psoriasis, folliculitis, herpes zoster, hirsutism, hyperglycemia, hypersensitivity reaction, localized vesiculation, pain, skin discoloration, skin hypertrophy, skin infection (application site), skin rash, telangiectasia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780949\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to betamethasone, other corticosteroids, or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cream, Lotion: Untreated bacterial, tubercular, and fungal skin infections; viral diseases (eg, herpes simplex, chicken pox, vaccinia)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Treatment of rosacea, acne vulgaris, perioral dermatitis, or pruritus without inflammation (foam); skin manifestations relating to tuberculosis or syphilis, eruptions following vaccinations; application to eyes (foam); &lt;18 years of age (patch). <b>Note:</b> Product labels may vary (refer also to product labels).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780950\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contact dermatitis: Allergic contact dermatitis can occur and is usually diagnosed by failure to heal rather than clinical exacerbation; discontinue use if irritation occurs and treat appropriately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to varicella zoster (chickenpox) should be avoided; corticosteroids should not be used to treat ocular herpes simplex.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin reactions: Discontinue if skin irritation or contact dermatitis occurs; do not use in patients with decreased skin circulation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing syndrome (rare), hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, application to large surface areas, or prolonged use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Use of augmented formulations in patients &lt;13 years of age is not recommended. For all formulations, children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients. Use lowest dose possible for shortest period of time to avoid HPA axis suppression.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Do not use occlusive dressings on weeping or exudative lesions and general caution with occlusive dressings should be observed; adverse effects may be increased. In the presence of a fungal or bacterial dermatologic infection, institute appropriate antifungal or antibacterial therapy. If the infection does not resolve promptly, discontinue use until the infection has been adequately controlled.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Augmented (eg, very high potency) products: Use of augmented formulations in patients &lt;13 years of age is not recommended. Not for treatment of rosacea, perioral dermatitis, or if skin atrophy is present at treatment site; not for facial, groin, axillary, oral, ophthalmic, or intravaginal use; not for use in a diapered area. Avoid concurrent use of other corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Flammable contents: Foam contains flammable propellants. Avoid fire, flame and smoking during and immediately following administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patch [Canadian product]: Has not been studied in psoriasis of the face, scalp or intertriginous areas; contains methyl and propyl parahydroxybenzoate, which may cause hypersensitivity (sometimes delayed).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: Withdraw therapy with gradual tapering of dose by reducing the frequency of application or substitution of a less potent steroid.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23781009\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23781008\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=94961&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780945\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780946\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed with corticosteroids in animal reproduction studies. Topical corticosteroids are preferred over systemic for treating conditions, such as psoriasis or atopic dermatitis in pregnant women; high potency corticosteroids are not recommended during the first trimester. Topical products are not recommended for extensive use, in large quantities, or for long periods of time in pregnant women (Bae 2011; Koutroulis 2011; Leachman 2006). Refer to the Betamethasone systemic monograph for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780948\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids are excreted in human milk. It is not known if systemic absorption following topical administration results in detectable quantities in human milk. Do not apply topical corticosteroids to nipples; hypertension was noted in a nursing infant exposed to a topical corticosteroid while nursing (Leachman 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">The manufacturer notes that when used systemically, maternal use of corticosteroids have the potential to cause adverse events in a nursing infant (eg, growth suppression, interfere with endogenous corticosteroid production) and therefore recommends that caution be exercised when administering betamethasone to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780979\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">HPA axis suppression and adrenal insufficiency, especially in children or with augmented formulation use. Foam, gel, lotion (augmented), and ointment (augmented): reassess if no improvement after 2 weeks of treatment. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780956\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Topical corticosteroids have anti-inflammatory, antipruritic, and vasoconstrictive properties. May depress the formation, release, and activity of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins) through the induction of phospholipase A<sub>2</sub> inhibitory proteins (lipocortins) and sequential inhibition of the release of arachidonic acid. Betamethasone has intermediate to very high range potency (dosage-form dependent).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780958\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Topical corticosteroids are absorbed percutaneously. The extent of absorption is dependent on several factors, including epidermal integrity (intact vs abraded skin), formulation, age of the patient, prolonged duration of use, and the use of occlusive dressings. Percutaneous absorption of topical steroids is increased in neonates (especially preterm neonates), infants, and young children.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine and bile</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780992\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Betamethasone Dipropionate Aug External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (15 g): $38.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Betamethasone Dipropionate External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (15 g): $44.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Betamethasone Valerate External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (45 g): $45.68</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Diprolene AF External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (15 g): $102.42</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Emulsion</b> (Sernivo External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (120 mL): $982.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Foam</b> (Betamethasone Valerate External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.12% (50 g): $326.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Foam</b> (Luxiq External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.12% (50 g): $537.32</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Betamethasone Dipropionate Aug External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (15 g): $61.48</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Lotion</b> (Betamethasone Dipropionate Aug External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (30 mL): $75.02</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Lotion</b> (Betamethasone Dipropionate External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (60 mL): $46.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Lotion</b> (Betamethasone Valerate External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (60 mL): $72.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Lotion</b> (Diprolene External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (30 mL): $117.72</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Betamethasone Dipropionate Aug External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (15 g): $63.52</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Betamethasone Dipropionate External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (15 g): $50.45</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Betamethasone Valerate External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (15 g): $20.89</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Diprolene External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (15 g): $108.54</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24799714\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Allerkan (PH);</li>\n      <li>Antroquoril (AU);</li>\n      <li>Bacort (PY);</li>\n      <li>Beavate (MY);</li>\n      <li>Beisong (CN);</li>\n      <li>Beloderm (HR, SK);</li>\n      <li>Bemon (DE);</li>\n      <li>Benosone (MY);</li>\n      <li>Beprogel (HK, SG, TH);</li>\n      <li>Bepronate (TH);</li>\n      <li>Beprosone (HK, ID, PH, SG, TH);</li>\n      <li>Besone (MY, TH);</li>\n      <li>Beta (NZ);</li>\n      <li>Betacort (PK);</li>\n      <li>Betacorten (IL);</li>\n      <li>Betaderm (LK, RO, SA, VE);</li>\n      <li>Betaduo (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Betagalen (DE);</li>\n      <li>Betaleb (LK);</li>\n      <li>Betamed (AE);</li>\n      <li>Betamousse (IE);</li>\n      <li>Betasone (HK, KW, LB, SA, ZW);</li>\n      <li>Betaval (BH, JO);</li>\n      <li>Betazon (BG);</li>\n      <li>Betesil (GB);</li>\n      <li>Betnelan (NL, QA);</li>\n      <li>Betneval (FR);</li>\n      <li>Betnikit (LK);</li>\n      <li>Betnoderm (PH, SE);</li>\n      <li>Betnovat (DK, IS, LT, NO, SE);</li>\n      <li>Betnovate (AE, AT, AU, BG, BH, BR, CH, CL, CY, CZ, EE, ES, GB, GR, HK, IE, IL, IN, JO, KW, LB, LK, MT, MX, NZ, PH, PL, PT, QA, SA, SG, TH, TR, UY, VE, VN);</li>\n      <li>Bettamousse (IL);</li>\n      <li>Camnovate (SG);</li>\n      <li>Celestoderm (FR);</li>\n      <li>Clinivate (TH);</li>\n      <li>Cortiderm (IN);</li>\n      <li>Cortival (AU);</li>\n      <li>Cremirit (CL);</li>\n      <li>Denvercort (AR);</li>\n      <li>Dermasone (SG);</li>\n      <li>Dermisole (LK);</li>\n      <li>Dermocort (BG);</li>\n      <li>Derzid (HK, SG);</li>\n      <li>Di An Song (CN);</li>\n      <li>Diprobet (LK);</li>\n      <li>Diprocel (HK, MY);</li>\n      <li>Diproderm (AT, DK, ES, FI, IS, NO, SE);</li>\n      <li>Diproforte (AT);</li>\n      <li>Diprolen (CH, DK, FI);</li>\n      <li>Diprolene (AE, BB, BE, BH, FR, JO, KW, NL, PH, PK, PL, QA, SA, TR);</li>\n      <li>Diprosone (AU, BE, BG, BH, BR, CO, CZ, DE, EG, FR, GB, HK, IT, JO, KW, LB, LU, MY, NL, NZ, PE, PH, PT, PY, QA, SA, SI, TH, VN);</li>\n      <li>DiproSone (MT);</li>\n      <li>Diprotop (TH);</li>\n      <li>Doprosone (AE);</li>\n      <li>Eleuphrat (AU);</li>\n      <li>Hexoderm (PY);</li>\n      <li>Lenovate (ZA);</li>\n      <li>Medobeta (SG, TR);</li>\n      <li>Molason (ID);</li>\n      <li>Novaderm (ZW);</li>\n      <li>Oviskin (ID);</li>\n      <li>Polynovate (TH);</li>\n      <li>Protocort (ID);</li>\n      <li>Repivate (ZA);</li>\n      <li>Soderm (UA);</li>\n      <li>Uniflex (HK, MY);</li>\n      <li>Vitacor (LK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bae YS, Van Voorhees AS, Hsu S, et al, &quot;Review of Treatment Options For Psoriasis in Pregnant or Lactating Women: From the Medical Board of the National Psoriasis Foundation,&quot; <i>J Am Acad Dermatol</i>, 2012, 67(3):459-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-topical-drug-information/abstract-text/22018758/pubmed\" target=\"_blank\" id=\"22018758\">22018758</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Betamethasone dipropionate cream, lotion, ointment [prescribing information]. South Plainfield, NJ: G &amp; W Laboratories; January 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Betamethasone dipropionate gel [prescribing information]. Madisonville, LA: Solubiomix LLC; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Betamethasone valerate cream, lotion, ointment [prescribing information]. Melville, NY: Fougera; July 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Betamethasone valerate foam [prescribing information]. Melville, NY: Fougera; June 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Beteflam (betamethasone valerate) [product monograph]. Mississauga, Ontario, Canada: Cipher Pharmaceuticals Inc; December 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boot AM, Nauta J, Hokken-Koelega AC, et al, &ldquo;Renal Transplantation and Osteoporosis,&rdquo; <i>Arch Dis Child</i>, 1995, 72(6):502-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-topical-drug-information/abstract-text/7618934/pubmed\" target=\"_blank\" id=\"7618934\">7618934</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bowman H and Lennard TW, &ldquo;Immunosuppressive Drugs,&rdquo; <i>Br J Hosp Med</i>, 1992, 48(9):570-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-topical-drug-information/abstract-text/1282440/pubmed\" target=\"_blank\" id=\"1282440\">1282440</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cooper MS and Stewart PM, &ldquo;Corticosteroid Insufficiency in Acutely Ill Patients,&rdquo; <i>N Engl J Med</i>, 2003, 348(8):727-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-topical-drug-information/abstract-text/12594318/pubmed\" target=\"_blank\" id=\"12594318\">12594318</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coursin DB and Wood KE, &ldquo;Corticosteroid Supplementation for Adrenal Insufficiency,&rdquo; <i>JAMA</i>, 2002, 287(2):236-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-topical-drug-information/abstract-text/11779267/pubmed\" target=\"_blank\" id=\"11779267\">11779267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diprolene AF (betamethasone dipropionate) cream [prescribing information]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme; November 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diprolene (betamethasone dipropionate) ointment [prescribing information]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diprolene (betamethasone dipropionate) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diprosone (betamethasone dipropionate) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gamsu HR, Mullinger BM, Donnai P, et al, &ldquo;Antenatal Administration of Betamethasone to Prevent Respiratory Distress Syndrome in Preterm Infants: Report of a UK Multicentre Trial,&rdquo; <i>Br J Obstet Gynaecol</i>, 1989, 96(4):401-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-topical-drug-information/abstract-text/2665800/pubmed\" target=\"_blank\" id=\"2665800\">2665800</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo; <i>J Natl Cancer Inst</i>, 2002, 94(22):1712-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-topical-drug-information/abstract-text/12441327/pubmed\" target=\"_blank\" id=\"12441327\">12441327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grotz WH, Mundinger FA, Gugel B, et al, &ldquo;Bone Mineral Density After Kidney Transplantation: A Cross-Sectional Study in 190-Graft Recipients Up to 20 Years After Transplantation,&rdquo; <i>Transplantation</i>, 1995, 59(7):982-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-topical-drug-information/abstract-text/7709459/pubmed\" target=\"_blank\" id=\"7709459\">7709459</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gutin PH, &ldquo;Corticosteroid Therapy in Patients With Brain Tumors,&rdquo; <i>Natl Cancer Inst Monogr</i>, 1977, 46:151-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-topical-drug-information/abstract-text/349394/pubmed\" target=\"_blank\" id=\"349394\">349394</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hochberg MC, Altman RD, April KT, et al, &ldquo;American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee,&rdquo; <i>Arthritis Care Res (Hoboken)</i>, 2012, 64(4):465-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-topical-drug-information/abstract-text/22563589/pubmed\" target=\"_blank\" id=\"22563589\">22563589</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kimberly RP, &ldquo;Glucocorticoids,&rdquo; <i>Curr Opin Rheumatol</i>, 1994, 6(3):273-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-topical-drug-information/abstract-text/8060761/pubmed\" target=\"_blank\" id=\"8060761\">8060761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koutroulis I, Papoutsis J, and Kroumpouzos G, &quot;Atopic Dermatitis in Pregnancy: Current Status and Challenges,&quot; <i>Obstet Gynecol Surv</i>, 2011, 66(10):654-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-topical-drug-information/abstract-text/22112526/pubmed\" target=\"_blank\" id=\"22112526\">22112526</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leachman SA and Reed BR, &quot;The Use of Dermatologic Drugs in Pregnancy and Lactation,&quot; <i>Dermatol Clin</i>, 2006, 24(2):167-97, vi.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-topical-drug-information/abstract-text/16677965/pubmed\" target=\"_blank\" id=\"16677965\">16677965</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lowenthal RM and Jestrimski KW, &ldquo;Corticosteroid Drugs: Their Role in Oncological Practice,&rdquo; <i>Med J Aust</i>, 1986, 144(2):81-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-topical-drug-information/abstract-text/2417096/pubmed\" target=\"_blank\" id=\"2417096\">2417096</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Luxiq (betamethasone valerate foam) [prescribing information]. Newtown, PA: Prestium Pharma; June 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Luxiq (betamethasone valerate) [Canadian product monograph]. Greenville, NC: Mayne Pharma Inc; March 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McGee S and Hirschmann J, &ldquo;Use of Corticosteroids in Treating Infectious Diseases,&rdquo; <i>Arch Intern Med</i>, 2008, 168(10):1034-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-topical-drug-information/abstract-text/18504331/pubmed\" target=\"_blank\" id=\"18504331\">18504331</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Report of a Workshop by the British Association for Paediatric Nephrology and Research Unit, Royal College of Physicians, &ldquo;Consensus Statement on Management and Audit Potential for Steroid Responsive Nephrotic Syndrome,&rdquo; <i>Arch Dis Child</i>, 1994, 70(2):151-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-topical-drug-information/abstract-text/8129444/pubmed\" target=\"_blank\" id=\"8129444\">8129444</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sernivo (betamethasone dipropionate spray) [prescribing information]. Princeton, NJ: Promius Pharma; February 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 94961 Version 111.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F23780933\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F23780934\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F23780937\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F23780969\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F23780968\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F23780970\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F24173866\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F23780971\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F23780990\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F23780936\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F46816957\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F23780975\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F23780941\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F23780928\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F23780952\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F23780949\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F23780950\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F23781009\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F23781008\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F23780945\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F23780946\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F23780948\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F23780979\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F23780956\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F23780958\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F23780992\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F24799714\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/94961|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=betamethasone-topical-patient-drug-information\" class=\"drug drug_patient\">Betamethasone (topical): Patient drug information</a></li><li><a href=\"topic.htm?path=betamethasone-topical-pediatric-drug-information\" class=\"drug drug_pediatric\">Betamethasone (topical): Pediatric drug information</a></li></ul></div></div>","javascript":null}